GI
ANIP icon

GAMMA Investing’s ANI Pharmaceuticals ANIP Stock Holding History

GAMMA Investing’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
1,572
+109
+7% +$8.74K ﹤0.01% 1610
2026
Q1 		$113K Buy
1,463
+41
+3% +$3.2K 0.01% 1579
2025
Q4 		$112K Sell
1,422
-83
-6% -$7.19K 0.01% 1494
2025
Q3 		$138K Buy
1,505
+126
+9% +$10.3K 0.01% 1239
2025
Q2 		$90K Sell
1,379
-40
-3% -$2.6K 0.01% 1532
2025
Q1 		$95K Buy
1,419
+881
+164% +$52.6K 0.01% 1303
2024
Q4 		$29.7K Sell
538
-14
-3% -$804 ﹤0.01% 2045
2024
Q3 		$32.9K Buy
552
+40
+8% +$2.44K ﹤0.01% 1782
2024
Q2 		$32.6K Buy
512
+51
+11% +$3.31K ﹤0.01% 1508
2024
Q1 		$31.9K Buy
461
+46
+11% +$2.78K 0.01% 1326
2023
Q4 		$23.2K Buy
+415
New +$22.9K 0.01% 1395

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAMMA Investing's ANIP Position: Q2 2026 in Review

GAMMA Investing increased its ANI Pharmaceuticals (ANIP) stake by 7.5% in Q2 2026, buying an estimated $8.74K and bringing the position to 1,572 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

GAMMA Investing first reported a position in ANIP in Q4 2023 and has held it in 11 quarters since. The position peaked at $138K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • GAMMA Investing held 1,572 shares of ANI Pharmaceuticals worth $130K as of Q2 2026.
  • GAMMA Investing bought 109 ANI Pharmaceuticals shares in Q2 2026, an estimated $8.74K.
  • ANI Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #1610 holding.
  • GAMMA Investing first reported a position in ANI Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's ANI Pharmaceuticals position peaked at $138K in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.